IMC-001
Our vaccination technology has already been successfully validated by immunogenicity examination and viral challenge studies in mouse and non-human primate models. In this project, we have developed a PD-1-enhanced therapeutic HIV DNA vaccine, termed ICVAX, that encodes for a soluble PD-1 domain fused to a bivalent chimeric HIV antigen. As a DNA vaccine, ICVAX can be repeatedly used to boost anti-HIV immune responses without issues of pre-existing immunity against vaccine vector. Its safety has also been demonstrated in preclinical GLP toxicity studies. Immuno Cure has recently completed the National Medical Products Administration (NMPA) approved Phase 1 clinical trial of IMC-001 in Mainland China; and in discussion with NMPA for a multi-center phase II trial.
IMC-003
Preclinical studies show that the IMC-003 vaccine, encoding a PD-1-linked tumour-associated antigen, provides effective control against established mesothelioma in combination with an immune checkpoint inhibitor in animal models. We are also developing new therapeutic vaccines targeting additional tumour-associated antigens for treating ovarian, cervical, colorectal, and lung cancers.
IMC-004
IMC-004 is a blocking antibody against ∆42PD1, a unique PD-1 isoform. Preclinical studies show that the antibody has potential therapeutic effects against inflammatory-related diseases, including cancers. We are currently conducting drug candidate optimisation. In addition, the efficacy of IMC-004 to treat liver and colorectal cancers is being evaluated in preclinical animal models.
IMC-005
We are currently developing novel needleless injection systems for DNA vaccination, aiming to improve DNA vaccine efficiency and to minimise the invasiveness of electroporation.